• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Girshick Birgit gifted 350 shares and bought $248,298 worth of shares (1,322 units at $187.82), increasing direct ownership by 53% to 44,449 units (SEC Form 4)

    11/21/23 5:07:01 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $CRL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Girshick Birgit

    (Last) (First) (Middle)
    251 BALLARDVALE STREET

    (Street)
    WILMINGTON MA 01887

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Corporate Executive VP & COO
    3. Date of Earliest Transaction (Month/Day/Year)
    03/01/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/01/2021 G 350 D $0 28,710(1) D
    Common Stock 11/20/2023 P 1,322 A $187.82 44,449(1) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The total in column 5 reflects the ownership as of the date of the transaction.
    /s/ Birgit Girshick 11/21/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CRL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRL

    DatePrice TargetRatingAnalyst
    5/8/2025$170.00In-line → Outperform
    Evercore ISI
    3/21/2025$190.00 → $170.00Buy → Neutral
    Goldman
    3/4/2025$155.00 → $175.00Sell → Neutral
    Citigroup
    3/3/2025$188.00Sell → Neutral
    Redburn Atlantic
    1/22/2025Outperform → Mkt Perform
    William Blair
    1/17/2025$250.00 → $185.00Buy → Neutral
    UBS
    11/18/2024$164.00Hold → Underperform
    CLSA
    11/7/2024$205.00Underperform → Hold
    CLSA
    More analyst ratings

    $CRL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Charles River Laboratories International Inc.

      SC 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

      11/8/24 10:52:38 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Charles River Laboratories International Inc.

      SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

      10/22/24 3:24:03 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by Charles River Laboratories International Inc. (Amendment)

      SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

      2/13/24 5:01:02 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Charles River Laboratories Announces First-Quarter 2025 Results

      – First-Quarter Revenue of $984.2 Million – – First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 – – Increases 2025 Guidance – – Repurchased $350 Million of Common Stock in First Quarter of 2025 – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6 million in the first quarter of 2024. The impact of foreign currency translation reduced reported revenue by 0.9%. Excluding this impact, revenue decreased 1.8% on an organic basis driven by declines in all three business segments. In the first quarter of 2025, the

      5/7/25 7:01:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

      – Board Approves Appointment of Four New Directors – – Strategic Planning and Capital Allocation Committee of the Board to Conduct Comprehensive Strategic Review of the Company's Business – – Enters into Cooperation Agreement with Elliott Investment Management – Charles River Laboratories International, Inc. (NYSE:CRL) today announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek re-election at the 2025 Annual Meeting of Shareholders. The Company also announced changes to its Board committees and a strategic review of the Company's business focused on enhancing long-term value for shareholders. Charles River's Board o

      5/7/25 7:00:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort

      Charles River Laboratories International, Inc. (NYSE:CRL) today announced the initial cohort of its Charles River Incubator Program (CIP). Launched in December 2024, the program offers early-stage biotechnology pioneers access to extensive scientific and commercial expertise and a wide ecosystem of discovery, development, and manufacturing capabilities to expedite the development of technologies and life-changing therapies for patients in need. The first cohort includes six advanced therapy and technology developers: 64x Bio, Adjuva Bio, Purilogics by Donaldson, Gordian Bio, NanoPalm, and NVI Therapeutics. Participants will benefit from tailored mentorship, consultative regulatory and qual

      4/29/25 8:00:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CRL
    Financials

    Live finance-specific insights

    See more
    • Corporate Executive VP & CFO Pease Flavia covered exercise/tax liability with 889 shares, decreasing direct ownership by 8% to 10,661 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      5/5/25 5:44:33 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Corporate Executive VP & COO Girshick Birgit gifted 430 shares, decreasing direct ownership by 0.78% to 54,628 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      2/26/25 4:18:10 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Chairman, President and CEO Foster James C bought $1,002,436 worth of shares (6,075 units at $165.01), increasing direct ownership by 3% to 183,639 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      2/21/25 4:41:25 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Laboratories Announces First-Quarter 2025 Results

      – First-Quarter Revenue of $984.2 Million – – First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 – – Increases 2025 Guidance – – Repurchased $350 Million of Common Stock in First Quarter of 2025 – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6 million in the first quarter of 2024. The impact of foreign currency translation reduced reported revenue by 0.9%. Excluding this impact, revenue decreased 1.8% on an organic basis driven by declines in all three business segments. In the first quarter of 2025, the

      5/7/25 7:01:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call

      Charles River Laboratories International, Inc. (NYSE:CRL) will release first-quarter 2025 financial results on Wednesday, May 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, May 7th, at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate the

      4/15/25 4:30:00 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance

      – Fourth-Quarter Revenue of $1.00 Billion and Full-Year Revenue of $4.05 Billion – – Fourth-Quarter GAAP Loss per Share of $(4.22) and Non-GAAP Earnings per Share of $2.66 – – Full-Year GAAP Earnings per Share of $0.20 and Non-GAAP Earnings per Share of $10.32 – – Provides 2025 Guidance – – Company Plans Stock Repurchases of Approximately $350 Million in 2025 – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth quarter and full-year 2024 and provided guidance for 2025. For the quarter, revenue was $1.00 billion, a decrease of 1.1% from $1.01 billion in the fourth quarter of 2023. The impact of foreign currency translation reduced report

      2/19/25 7:00:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Charles River upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Charles River from In-line to Outperform and set a new price target of $170.00

      5/8/25 8:24:10 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River downgraded by Goldman with a new price target

      Goldman downgraded Charles River from Buy to Neutral and set a new price target of $170.00 from $190.00 previously

      3/21/25 8:03:14 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River upgraded by Citigroup with a new price target

      Citigroup upgraded Charles River from Sell to Neutral and set a new price target of $175.00 from $155.00 previously

      3/4/25 7:20:42 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Charles River Laboratories International Inc.

      10-Q - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

      5/7/25 9:09:41 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Laboratories International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

      5/7/25 7:15:48 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Laboratories International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

      5/7/25 7:08:39 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    Leadership Updates

    Live Leadership Updates

    See more
    • Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

      – Board Approves Appointment of Four New Directors – – Strategic Planning and Capital Allocation Committee of the Board to Conduct Comprehensive Strategic Review of the Company's Business – – Enters into Cooperation Agreement with Elliott Investment Management – Charles River Laboratories International, Inc. (NYSE:CRL) today announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek re-election at the 2025 Annual Meeting of Shareholders. The Company also announced changes to its Board committees and a strategic review of the Company's business focused on enhancing long-term value for shareholders. Charles River's Board o

      5/7/25 7:00:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery

      Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Autobahn Labs Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn's Board of Directors Charles River Laboratories International, Inc. (NYSE:CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn's grow

      7/24/24 8:00:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors

      Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board of Directors. Ms. Kemps-Polanco has extensive pharmaceutical industry experience in leading commercial organizations that will provide a wealth of healthcare business leadership knowledge and sales and marketing expertise to Charles River's Board. As a member of the Board, Ms. Kemps-Polanco will serve on the Compensation and Strategic Planning and Capital Allocation Committees. "Reshema Kemp-Polanco's deep industry experience at two of the top-10, global pharmaceutical companies and demonstrated

      1/24/24 4:30:00 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman, President and CEO Foster James C bought $1,002,436 worth of shares (6,075 units at $165.01), increasing direct ownership by 3% to 183,639 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      2/21/25 4:41:25 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Corporate Executive VP & COO Girshick Birgit bought $249,250 worth of shares (1,514 units at $164.63), increasing direct ownership by 3% to 55,058 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      2/21/25 4:38:37 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Girshick Birgit gifted 350 shares and bought $248,298 worth of shares (1,322 units at $187.82), increasing direct ownership by 53% to 44,449 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      11/21/23 5:07:01 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care